|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005773,
umls-concept:C0016263,
umls-concept:C0030705,
umls-concept:C0109317,
umls-concept:C0150369,
umls-concept:C0181904,
umls-concept:C0280100,
umls-concept:C0596972,
umls-concept:C0728873,
umls-concept:C0752312,
umls-concept:C0920321,
umls-concept:C1150579,
umls-concept:C1174389,
umls-concept:C1314939,
umls-concept:C1332153,
umls-concept:C1333340,
umls-concept:C1366882,
umls-concept:C1370600,
umls-concept:C1516119,
umls-concept:C1521743,
umls-concept:C1704259,
umls-concept:C1704646,
umls-concept:C1705767,
umls-concept:C1705791,
umls-concept:C1705987,
umls-concept:C1709518,
umls-concept:C1879547
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-4-25
|
|
pubmed:abstractText |
We previously reported a flow cytometry technique to monitor pharmacodynamic effects of the raf kinase inhibitor BAY 43-9006 based on the ability of phorbol ester (PMA) to phosphorylate extracellular-regulated kinase (ERK) in peripheral blood (Chow et al., Cytometry 2001;46:72-78). In this article, we describe its application to phase I trials of BAY 43-9006 in solid tumor and AML/MDS patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD13,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates,
http://linkedlifedata.com/resource/pubmed/chemical/CD33 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP...,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Stem Cell Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tetradecanoylphorbol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/sorafenib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1552-4949
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2006 International Society for Analytical Cytology.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
107-14
|
|
pubmed:dateRevised |
2009-12-11
|
|
pubmed:meshHeading |
pubmed-meshheading:16498671-Aged,
pubmed-meshheading:16498671-Aged, 80 and over,
pubmed-meshheading:16498671-Antigens, CD,
pubmed-meshheading:16498671-Antigens, CD13,
pubmed-meshheading:16498671-Antigens, CD3,
pubmed-meshheading:16498671-Antigens, CD34,
pubmed-meshheading:16498671-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:16498671-Benzenesulfonates,
pubmed-meshheading:16498671-Drug Monitoring,
pubmed-meshheading:16498671-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:16498671-Flow Cytometry,
pubmed-meshheading:16498671-Hemolysis,
pubmed-meshheading:16498671-Humans,
pubmed-meshheading:16498671-Leukemia, Myeloid, Acute,
pubmed-meshheading:16498671-Leukocytes, Mononuclear,
pubmed-meshheading:16498671-MAP Kinase Signaling System,
pubmed-meshheading:16498671-Middle Aged,
pubmed-meshheading:16498671-Models, Biological,
pubmed-meshheading:16498671-Myelodysplastic Syndromes,
pubmed-meshheading:16498671-Neoplasms,
pubmed-meshheading:16498671-Phosphorylation,
pubmed-meshheading:16498671-Pyridines,
pubmed-meshheading:16498671-Stem Cell Factor,
pubmed-meshheading:16498671-Stem Cells,
pubmed-meshheading:16498671-Tetradecanoylphorbol Acetate
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
|
|
pubmed:affiliation |
Department of Pathology, Princess Margaret Hospital, Toronto, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
